ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO931

Osteoprotegerin Is Associated with Development of Coronary Artery Calcification but Not Severity and Progression in Non-Dialysis CKD: Results from the KNOW CKD Study

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Baek, Seon Ha, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, Korea (the Republic of)
  • Choi, Sun Ryoung, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, Korea (the Republic of)
  • Seo, Jang Won, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, Korea (the Republic of)
  • Koo, Ja-Ryong, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, Korea (the Republic of)
  • Kim, Sejoong, Seoul National University Bundang Hospital, Seongnam, GyeonGgi-Do, Korea (the Republic of)
  • Chin, Ho Jun, Seoul National University Bundang Hospital, Seongnam, GyeonGgi-Do, Korea (the Republic of)
  • Chae, Dong-Wan, Seoul National University Bundang Hospital, Seongnam, GyeonGgi-Do, Korea (the Republic of)

Group or Team Name

  • KNOW CKD group
Background

Coronary artery calcifications (CAC) are recognized as a predictor of all-cause and cardiovascular mortality in chronic kidney disease (CKD). Osteoprotegerin (OPG) could be a marker of vascular calcification presence and extent. The purpose of this study was to evaluate relationships between OPG levels and presence/severity/progression of CAC score in non-dialyzed CKD patients.

Methods

We prospectively enrolled 1974 CKD patients (1180 male/794 female, mean age: 53.2 years) who had OPG and electron beam computed tomography (CT) or multi-detector CT for CAC scoring at baseline. A CAC score of > 400 Agatston unit (AU) s was used to define severe CAC. In term of definition for CAC progression: among those with no baseline CAC, incidence was defined as an annual increase in CAC score ≥ 5 AUs. Among those with baseline CAC, progression was defined as 15% annual increase.

Results

Mean serum concentrations of OPG amounted to 6.79 ± 3.53 pmol/L. Among 1974 patients, 1011 (51.2 %) had CAC score >0 and 209 (10.6 %) had scores > 400. Higher OPG levels were associated with the present CAC but not severe CAC at baseline. [LnOPG, presence: OR =2.033, P = 0.001; severe CAC: OR =1.700, P =0.070]. Among 827 patients with 4-year follow up CAC scores, 22 (4.9%) participants without CAC at baseline had incident CAC and 243 (63.8%) participants with CAC at baseline had CAC progression. Among subjects without CAC at baseline, higher OPG levels were associated with incident CAC (LnOPG, OR = 5.045. P = 0.042). However, OPG were not associated with CAC progression among participants with CAC at baseline or in total.

Conclusion

Our results indicated that higher serum OPG levels are associated with the presence and development of CAC non-dialyzed CKD patients. However, OPG does not seem to be involved in severity and progression of CAC.

Funding

  • Government Support - Non-U.S.